این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۲۰، شماره ۱، صفحات ۱۴-۲۹
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Feasibility and Effectiveness of CALGB 10403 protocol in Adolescent and Young Adult Patients with Acute Lymphoblastic leukemia/ Lymphoblastic Lymphoma: A Study at Seyed Al-Shohada Hospital, Isfahan, Iran
چکیده انگلیسی مقاله Background: Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) are rare blood cancers with poorer survival in adolescents and young adults (AYAs) than in children. Pediatric-inspired regimens like CALGB 10403 have improved outcomes in AYAs. This study evaluated the effectiveness, feasibility, and treatment-related toxicities of CALGB 10403 in AYAs with ALL/LBL treated at Seyed Al-Shohada Hospital, Isfahan, Iran, from December 2021 to May 2024 Materials and Methods: AYAs aged 17-39 with newly diagnosed ALL/LBL (excluding Burkitt, Ph+, and prior treatment) were included.  Baseline characteristics and outcomes of interest (induction response, event-free and overall survivals) were collected.  Induction response was assessed via bone marrow (ALL) or CT scan/biopsy (LBL). Minimal residual disease (MRD) was evaluated by flow cytometry. Treatment-related toxicities were monitored and graded per CTCAE criteria. The feasibility of implementing the CALGB 10403 protocol was evaluated by measuring treatment delays. Results: Seventeen AYA patients with newly diagnosed ALL/LBL (median age 21) were enrolled, mostly male (14/17). Fourteen had ALL, and three had LBL. Extramedullary involvement was seen in 29%, including lymphadenopathy, bulky mediastinal masses, and CNS involvement. Sixteen patients (94%) achieved remission, with no deaths during the induction course. One-year EFS and OS were 77% and 100%, respectively. Common toxicities included hyperbilirubinemia, elevated transaminases, and infections. Treatment delays, mainly from non-adherence, occurred in 53%. Eight patients achieved MRD negativity after Course I. Conclusion: This study provides insights into the first Iranian experience with the CALGB 10403 protocol for AYAs with ALL/LBL, a regimen that has demonstrated encouraging survival outcomes in U.S. trials.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Padideh Oghab
Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


| Ali Erfan
Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


| Mohadese Poorpoone
Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


| Mohammadsaleh Peikar
Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
نشانی اینترنتی https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2458
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات